• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Patterson's Moonshot Implosion

anonymous

Guest
Stock price took a massive nosedive today on the heels of losing the CEREC exclusivity. Bad decisions from a floundering group of executives that are totally out of touch with their market. The multi-million dollar "moonshot" mission blew up in their faces. Probably 200million in cerec inventory that they're going to have to offload now. The fun is just beginning. Time to shake the shit out of the top of the company and not the people in the middle.
 
  • Like
Reactions: Karmanow




look the loss of the exclusive was a forgone conclusion as we all know it. But the real kick in the balls today for the stock was missing the earnings target that Wall Street had for the company. Sure getting kicked while down wasn't good with the Sirona thing but, me thinks there's something afoot aside from the idiots in Minnesota truly being in over their heads... The cutting of staff, the closing of branches, exclusivity gone... And to announce it before years end?? Hmmmm.
 
  • Like
Reactions: Karmanow